BrainsWay Ltd. (NASDAQ:BWAY) Short Interest Update

BrainsWay Ltd. (NASDAQ:BWAY) was the target of a significant drop in short interest during the month of February. As of February 28th, there was short interest totalling 55,300 shares, a drop of 31.0% from the February 13th total of 80,200 shares. Approximately 0.4% of the company’s shares are short sold. Based on an average trading volume of 65,600 shares, the short-interest ratio is currently 0.8 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $16.00 price target on shares of BrainsWay in a research report on Wednesday, March 12th.

BrainsWay Stock Performance

Shares of BWAY stock opened at $10.21 on Tuesday. The stock has a market capitalization of $192.22 million, a P/E ratio of 102.11 and a beta of 1.29. The company has a 50 day moving average price of $10.27 and a 200 day moving average price of $9.64. BrainsWay has a fifty-two week low of $4.61 and a fifty-two week high of $11.79.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. grew its holdings in shares of BrainsWay by 316.3% in the third quarter. JPMorgan Chase & Co. now owns 14,769 shares of the company’s stock valued at $136,000 after purchasing an additional 11,221 shares in the last quarter. Rhumbline Advisers lifted its stake in BrainsWay by 10.8% in the fourth quarter. Rhumbline Advisers now owns 21,966 shares of the company’s stock worth $207,000 after acquiring an additional 2,144 shares during the last quarter. ARK Investment Management LLC purchased a new position in BrainsWay in the fourth quarter worth approximately $1,656,000. Two Sigma Investments LP lifted its stake in BrainsWay by 2.0% in the fourth quarter. Two Sigma Investments LP now owns 92,755 shares of the company’s stock worth $875,000 after acquiring an additional 1,786 shares during the last quarter. Finally, Two Sigma Advisers LP lifted its stake in BrainsWay by 32.6% in the fourth quarter. Two Sigma Advisers LP now owns 60,600 shares of the company’s stock worth $571,000 after acquiring an additional 14,900 shares during the last quarter. Institutional investors and hedge funds own 30.11% of the company’s stock.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.